×

K2M Announces Completion of First Surgical Case Using CAPRI(TM) Corpectomy Cage System

LEESBURG, Va., Dec. 22, 2014 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq:KTWO) (the "Company" or "K2M"), a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine technologies, techniques and minimally invasive procedures, today announced the completion of the first surgical case using the Company's CAPRI Corpectomy Cage System, an expandable vertebral body replacement device that provides structural stability following a corpectomy or vertebrectomy. The first surgical case was performed by Dr. Stefano Boriani at Rizzoli Hospital in Bologna, Italy.

"The CAPRI Corpectomy Cage offers surgeons a truly innovative cage system that is designed to allow for continuous height expansion and endplate angulation," said Dr. Boriani. "Due to this unique design and functionality, I was able to adjust the cage in-situ to engage the patient's inferior and superior vertebral body endplates. I am very pleased with the design, functionality and ease of use."

The CAPRI Corpectomy Cage System is intended for use in the thoracolumbar spine (T1 to L5) to replace collapsed, damaged or unstable vertebral bodies due to tumor or trauma (i.e., fracture). The System is designed to provide anterior spinal column support even in the absence of fusion for a prolonged period.

CAPRI cages, manufactured from titanium and cobalt chrome, are offered in a variety of interchangeable footprint options, allowing for in-situ height expansion and endplate angulation to match the patient's anatomy. Additionally, the device may be implanted through an anterior, lateral or posterior approach.

"We are pleased to announce the successful completion of the first surgical case using CAPRI," stated Eric Major, K2M's President and CEO. "This milestone reinforces K2M's commitment to establishing ourselves as the global leader in providing solutions for complex spinal pathologies."

On Nov. 12, K2M announced it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market CAPRI in the United States. The Company also recently received the CE Mark to expand the Company's global distribution of the product.

For more information on K2M's complete product portfolio, visit www.K2M.com.

About K2M

K2M Group Holdings, Inc. is a global medical device company focused on designing, developing and commercializing innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most difficult and challenging spinal pathologies. K2M has leveraged these core competencies to bring to market an increasing number of products for patients suffering from degenerative spinal conditions. These technologies and techniques, in combination with a robust product pipeline, enable the Company to favorably compete in the global spinal surgery market. Additional information is available online at www.K2M.com.

Forward-Looking Statements

Certain statements made in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are based on management's expectations, estimates, projections, and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Additional information regarding these factors is contained in the Company's Registration Statement on Form S-1 filed with the SEC.

Find K2M on Facebook: https://www.facebook.com/K2MInc
Follow K2M on Twitter: http://twitter.com/K2MInc
Watch K2M on YouTube: http://www.youtube.com/user/K2MInc

CONTACT: Media Contact Zeno Group on behalf K2M Group Holdings, Inc. Marcie Kohenak, 202-965-7811 Marcie.Kohenak@ZenoGroup.com

Source:K2M Group Holdings, Inc.